JAN (NYSE:JAN) Stock Has Consensus Price Target of $32.44

JAN (NYSE:JAN) has earned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $32.44.

A number of equities research analysts recently weighed in on JAN shares. UBS Group set a $29.00 price objective on JAN in a research note on Thursday, June 18th. Scotiabank boosted their target price on shares of JAN from $31.00 to $33.00 and gave the stock a “sector outperform” rating in a report on Thursday, September 17th. Morgan Stanley increased their price target on shares of JAN from $28.00 to $31.00 and gave the company an “overweight” rating in a research report on Tuesday, August 18th. Compass Point started coverage on shares of JAN in a report on Wednesday, September 16th. They issued a “neutral” rating and a $37.00 price target on the stock. Finally, Huntington started coverage on shares of JAN in a research note on Thursday, September 10th. They set an “outperform” rating and a $36.00 price objective for the company.

JAN Trading Up 0.2%

NYSE JAN opened at $28.16 on Tuesday. The firm’s 50 day moving average price is $30.15 and its 200-day moving average price is $27.93. JAN has a 52-week low of $22.76 and a 52-week high of $32.83.

JAN (NYSE:JAN) last posted its earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The business had revenue of $216.46 million during the quarter, compared to the consensus estimate of $203.32 million. The firm’s revenue for the quarter was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. As a group, research analysts expect that JAN will post 0.97 earnings per share for the current fiscal year.

JAN Announces Dividend

The company also recently declared a monthly dividend, which will be paid on Tuesday, December 29th. Shareholders of record on Friday, December 18th will be issued a $0.0475 dividend. This represents a $0.57 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Friday, December 18th.

Institutional Trading of JAN

Several hedge funds and other institutional investors have recently made changes to their positions in JAN. Engineers Gate Manager LP purchased a new position in JAN during the 2nd quarter worth $15,274,000. Wellington Management Group LLP purchased a new stake in JAN in the second quarter valued at about $8,739,000. WINTON GROUP Ltd acquired a new stake in JAN in the second quarter worth about $2,985,000. Readystate Asset Management LP acquired a new stake in JAN in the second quarter worth about $1,724,000. Finally, Greenland Capital Management LP purchased a new stake in shares of JAN during the second quarter worth about $575,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.

Key Stories Impacting JAN

Here are the key news stories impacting JAN this week:

• Neutral Sentiment: With no fresh announcements, the stock’s modest increase appears driven by normal trading activity rather than a new earnings release, acquisition, analyst action, or other identifiable catalyst.
• Neutral Sentiment: Investors continue to weigh JAN’s recent fundamentals: quarterly revenue rose 45.4% year over year to $216.5 million, but adjusted earnings of $0.05 per share missed the $0.23 consensus estimate. Management’s fiscal 2026 EPS guidance remains $0.95–$0.98.
• Negative Sentiment: The stock remains below its 50-day moving average, which may indicate continued near-term technical pressure, although it is slightly above its 200-day average.

About JAN

JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.